Harmony Biosciences Holdings, Inc. (HRMY): Cash & Equivalents
$752.50M
As of 2025-12-31
$549.77M
As of 2026-06-30
+45.6%
3-year compound annual growth
+26.9%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $752.50M | +66.1% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $453.00M | +45.4% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $311.66M | +27.8% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $243.78M | +4.0% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $234.31M | +2.5% | 2023-02-21, Balance as of period end |
| 2020-12-31 | $228.63M | +834.8% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $24.46M | n/a | 2021-03-25, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $752.50M | +66.1% |
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $285.58M | +97.1% |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $372.26M | +53.8% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | $198.69M | +98.7% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $231.25M | +227.7% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $120.50M | -5.6% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $205.40M | +106.4% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $158.54M | -42.7% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $170.18M | +12.2% |
Compare HRMY, ANIP, IONS, MDGL side by side · Screen every company in Pharmaceutical Preparations ↗